Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06903338 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv11
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 120 to confirmed 124
    • Site details revised at 39 of 39 sites
    v10
  3. Study sites: 34 to 39v9
  4. Study sites: 28 to 34v8
  5. Study sites: 18 to 28v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 12 to 18v6
  2. Study sites: 9 to 12v5
  3. Study sites: 6 to 9v4
  4. Study sites: 5 to 6v3
  5. Study sites: 4 to 5v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
Trial Details
NCT Number NCT06903338
Lead Sponsor Vir Biotechnology, Inc.
Conditions
(from sponsor)		 Viral Hepatitis
Related terms Hepatitis, Hepatitis D, Hepatitis D, Chronic
Enrollment 124 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov